Our previous studies in rats with ablation nephrectomy have shown similar cardiorenal protective effects of renin-angiotensin system (RAS)-dependent treatment (combination of angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker) and RAS-independent treatment (combination of α- and β-adrenoreceptor antagonist and diuretics). Moreover, selective blockade of endothelin (ET) receptor type A (ETA) improved survival rate and attenuated hypertension and organ damage in Ren-2 transgenic rats. Therefore, we were interested in whether ETA receptor blockade could have additive effects to the classical blockade of the RAS. Transgenic rats underwent 5/6 renal ablation at the age of 2 months and were treated for 20 weeks with RAS blockers alone (angiotensin II receptor blocker – losartan, and angiotensin-converting enzyme inhibitor – trandolapril), ETA receptor blocker alone (atrasentan) or with the combination of RAS and ETA receptor blockade. RAS blockade normalized blood pressure and improved survival. It decreased cardiac hypertrophy and proteinuria as well as tissue angiotensin II and ET-1 levels. In contrast, ETA receptor blockade only partially improved survival rate, reduced blood pressure, attenuated the development of cardiac hypertrophy and transiently reduced proteinuria. However, no additive cardio- and renoprotective effects of ETA and RAS blockade were noted at the end of the study.

Keywords:
5/6 nephrectomy, End-organ damage, Hypertension, Endothelin receptor type A, AT1 receptor blocker
1.
Kobori H, Nangaku M, Navar LG, Nishiyama A: The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007;59:251–287.
2.
Hall JE, Brands MW: The renin-angiotensin-aldosterone system: renal mechanisms and circulatory homeostasis; in Seldin DW, Giebisch G (eds): The Kidney: Physiology and Pathophysiology. Philadelphia, Lippincott Williams & Wilkins, 2000, pp 1009–1046.
3.
Kohan DE, Rossi NF, Inscho EW, Pollock DM: Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev 2011;91:1–77.
4.
Barton M: Therapeutic potential of endothelin receptor antagonists for chronic proteinuric renal disease in humans. Biochem Biophys Acta 2010;1802:1203–1213.
5.
Baumeister SE, Boeger CA, Kraemer BK, Doring A, Eheberg D, Fischer B, John J, Koenig W, Meiwsinger C: Effect of chronic kidney disease and comorbid conditions on health care costs: a 10-year observational study in a general population. Am J Nephrol 2011;31:222–229.
6.
Remuzzi G, Benigni A, Remuzzi A: Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006;116:288–296.
7.
Tedla FM, Brar A, Browne R, Brown C: Hypertension in chronic kidney disease: navigating the evidence. Int J Hypertens 2011;2011:132405.
8.
Alfie J, Aparicio LS, Waisman GD: Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system. Rev Recent Clin Trials 2011;6:134–146.
9.
Gordon J, Kopp JB: Off the beaten renin-angiotensin-aldosterone system pathway: new perspectives on antiproteinuric therapy. Adv Chron Kidney Dis 2011;18:300–311.
10.
Barton M: Therapeutic potential of endothelin receptor antagonists for chronic proteinuric renal disease in humans. Biochem Biophys Acta 2010;1802:1203–1213.
11.
Gagliardinin E, Corna D, Zoja C, Sangalli F, Carrara F, Rosi M, Conti S, Rottoli D, Longaretti L, Remuzzi A, Remuzzi G, Benigni A: Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. Am J Physiol 2009;297:F1448–F1456.
12.
Zoja C, Cattaneo S, Fiordaliso F, Lionetti V, Zambelli V, Salio M, Corna D, Pagani C, Rottoli D, Bisighini C, Remuzzi G, Benigni A: Distinct cardiac and renal effects of ETA receptor antagonist and ACE inhibitir in experimental type 2 diabetes. Am J Physiol 2011;301:F1114–F1123.
13.
Amann K, Simonaviciene A, Medwedewa T, Koch A, Orth S, Gross ML, Haas C, Kuhlmann A, Linz W, Scholkens B, Ritz E: Blood pressure-independent additive effects of pharmacologic blockade of the renin-angiotensin and endothelin systems on progression in a low-renin model of renal damage. J Am Soc Nephrol 2001;12:2572–2584.
14.
Adams J, Odoni G, Ogata H, Viedt C, Amann K, Ritz E, Orth SR: Combination treatment with an ETA receptor blocker and an ACE inhibitor is not superior to the respective monotherapies in attenuating chronic transplant nephropathy in a Fisher to Lewis rat model. Nephrol Dial Transplant 2002;17:780–787.
15.
Mullins JJ, Peters J, Ganten D: Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 1990;344:541–544.
16.
Vaneckova I, Kramer HJ, Backer A, Vernerova Z, Opocensky M, Cervenka L: Early endothelin-A receptor blockade decreases blood pressure and ameliorates end-organ damage in homozygous Ren-2 rats. Hypertension 2005;46:969–974.
17.
Vaneckova I, Kramer HJ, Backer A, Schejbalova S, Vernerova Z, Eis V, Opocensky M, Dvorak P, Cervenka L: Early-onset endothelin receptor blockade in hypertensive heterozygous Ren-2 rats. Vascul Pharmacol 2006;45:163–170.
18.
Vernerova Z, Kramer HJ, Backer A, Cervenka L, Opocensky M, Huskova Z, Vanourkova Z, Eis V, Čertíková Chábová V, Tesar V, Maly J, Vaneckova I: Late-onset endothelin receptor blockade in hypertensive heterozygous Ren-2 transgenic rats. Vascul Pharmacol 2008;48:165–173.
19.
Opocensky M, Kramer HJ, Backer A, Vernerova Z, Eis V, Cervenka L, Certikova C, V, Tesar V and Vaneckova I: Late-onset endothelin-A receptor blockade reduces podocyte injury in homozygous Ren-2 rats despite severe hypertension. Hypertension 2006;48:965–971.
20.
Kujal P, Chabova VC, Vernerova Z, Walkowska A, Kompanowska-Jezierska E, Sadowski J, Vanourkova Z, Huskova Z, Opocensky M, Skaroupkova P, Schejbalova S, Kramer HJ, Rakusan D, Maly J, Netuka I, Vaneckova I, Kopkan L, Cervenka L: Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects? Clin Exp Pharmacol Physiol 2010;37:1159–1169.
21.
Kurtz TW, Griffin KA, Bidani AK, Davisson RL, Hall JE: Recommendations for blood pressure measurements in humans and experimental animals. 2. Blood pressure measurements in experimental animals. Hypertension 2005;45:299–310.
22.
Kopkan L, Husková Z, Vaňourková Z, Thumová M, Škaroupková P, Malý J, Kramer HJ, Dvořák P, Červenka L: Reduction of oxidative stress does not attenuate the development of angiotensin II-dependent hypertension in Ren-2 transgenic rats. Vascul Pharmacol 2009;51:175–181.
23.
Huskova Z, Kramer HJ, Thumova M, Vanourkova Z, Burgelova M, Teplan V, Maly J, Cervenka L: Effects of anesthesia on plasma and kidney ANG II levels in normotensive and ANG II-dependent hypertensive rats. Kidney Blood Press Res 2006;29:74–83.
24.
Čertíková Chábová V, Walkowska A, Kompanowska-Jezierska E, Sadowski J, Kujal P, Vernerová Z, Vaňourková Z, Kopkan L, Kramer HJ, Falck JR, Imig JD, Hammock BD, Vaněčková I, Červenka L: Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats. Clin Sci 2010;118:617–632.
25.
Nakano Y, Hirano T, Uehara K, Nishibayashi S, Hattori K, Aihara M, Yamada Y: New rat model induced by anti-glomerular basement membrane antibody shows sever glomerular adhesion in early stage and quickly progresses to end-stage renal failure. Pathol Int 2008;58;361–370.
26.
Lane PH, Steffes MW, Mauer MS: Estimation of glomerular volume: a comparison of four methods. Kidney Int 1992;41:1085–1089.
27.
Matsusaka T, Nishimura H, Utsunomia H, Kakuchi J, Nimura F, Inagami T, Fogo A, Ichikawa I: Chimeric mice carrying ‘regional’ targeted deletion of the angiotensin type 1A receptor gene: evidence against the role for local angiotensin in the in vivo feedback regulation of renin synthesis in juxtaglomerular cells. J Clin Invest 1996;98:1867–1877.
28.
Červenka L, Vaněčková I, Husková Z, Vaňourková Z, Erbanová M, Thumová M, Škaroupková P, Opočenský M, Malý J, Čertíková Chábová V, Tesař V, Bürgelová M, Viklický O, Teplan V, Želízko M, Kramer HJ, Navar LG: Pivotal role of AT1A receptors in the development of two-kidney, one-clip hypertension: study in AT1A receptor knockout mice. J Hypertens 2008;26:1379–1389.
29.
Crowley SD, Gurley SB, Herrera MJ, Ruiz P, Griffith R, Kumar AP, Smithies O, Le TH, Coffman TM: Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci 2006;103:17985–17990.
30.
Iglarz M, Clozel M: At the heart of tissue: endothelin system and end-organ damage. Clin Sci 2010;119:453–463.
31.
Vernerová Z, Kujal P, Kramer HJ, Backer A, Cervenka L, Vaněčková I: End-organ damage in hypertensive Ren-2 rats: influence of early and late endothelin blockade. Physiol Res 2009;58(suppl 2):S69–S78.
32.
Barton M, Shaw S, d´Uscio LV, Moreau P, Luscher TF: Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation. Biochem Biophys Res Commun 1997;238:861–865.
33.
Vaňourková Z, Kramer HJ, Husková Z, Červenka L, Vaněčková I: Despite similar reduction of blood pressure and renal ANG II and ET-1 levels aliskiren but not losartan normalizes albuminuria in hypertensive Ren-2 rats. Physiol Res 2010;59:339–345.
34.
Yoshida Y, Kawamura T, Ikoma M, Fogo A, Ichikawa I: Effects of antihypertensive drugs on glomerular morphology. Kidney Int 1989;36:626–635.
35.
Dworkin LD, Feiner HD, Parker M, Tolbert E: Effects of nifedipine and enalapril on glomerular structure and function in uninephrectomized SHR. Kidney Int 1991;39:1112–1117.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.